Physician profile
Vu T Ho
NPI 1871574871
$3,833.05
in general payments reported to CMS, 2019-2025
47 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $99.71 · 2021: $11.92 · 2022: $315 · 2023: $395 · 2024: $848 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.24 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $514.78 | 2019-2025 | |
| Daiichi Sankyo INC. | $335.35 | 2022-2025 | Enhertu, Datroway |
| Pfizer INC. | $324.27 | 2019-2025 | |
| Gilead Sciences, INC. | $240.10 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $190.69 | 2023-2025 | Zoladex |
| Astellas Pharma US INC | $149.16 | 2022-2025 | Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $134.36 | 2020-2025 | Opdivo |
| Allergan, INC. | $122.95 | 2019 | |
| Taiho Oncology, INC. | $117.85 | 2024-2025 | |
| Eisai INC. | $113.73 | 2020-2025 | |
| Medtronic, INC. | $107.39 | 2023 | Endoflip |
| Array Biopharma INC | $104.98 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $96.85 | 2024-2025 | Fruzaqla, Alunbrig |
| Csl Behring | $84.58 | 2023-2025 | Afstyla, Idelvion, Hemgenix |
| Janssen Biotech, INC. | $80.98 | 2025 | Talvey, Darzalex, Tecvayli |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.